サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1269442

抗高脂血症薬市場- 世界の産業分析、規模、シェア、成長、動向、予測、2022-2031年

Antihyperlipidemic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 207 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗高脂血症薬市場- 世界の産業分析、規模、シェア、成長、動向、予測、2022-2031年
出版日: 2023年03月13日
発行: Transparency Market Research
ページ情報: 英文 207 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗高脂血症薬市場- 調査範囲：

本レポートでは、2022年を基準年、2031年を予測年として考え、2017年から2031年までの世界の抗高脂血症薬市場の収益を提供します。また、2022年から2031年までの世界の抗高脂血症薬市場のCAGRを掲載しています。

本レポートは、広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行っています。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、抗高脂血症薬市場を把握しました。

本レポートは、世界の抗高脂血症薬市場の競合情勢を掘り下げています。世界の抗高脂血症薬市場で活動する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の抗高脂血症薬市場におけるプレイヤーの属性です。

目次

第1章 序文

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場の概要

  • イントロダクション
    • 薬効分類の定義
    • 業界の進化と発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界市場の分析と予測、2017年～2031年

第5章 主な洞察

  • パイプラインの分析
  • 主要な業界イベント
  • 地域別/世界別の規制シナリオ
  • COVID-19パンデミックの業界への影響（バリューチェーンと短期/中期/長期的な影響）

第6章 世界市場の分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：薬効分類別、2017年～2031年
    • スタチン系薬剤
    • 胆汁酸セクレタント
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場魅力分析：薬物クラス別

第7章 世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第8章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場規模予測：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ地域
  • 市場魅力分析：地域別

第9章 北米市場の分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • スタチン系薬剤
    • 胆汁酸セクレタント
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国別、2017-2031年
    • 米国
    • カナダ
  • 市場魅力分析
    • 薬剤クラス別
    • 流通チャネル別
    • 国別

第10章 欧州市場の分析と予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • スタチン系薬剤
    • 胆汁酸セクレタント
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国・小地域別、2017-2031年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 市場魅力分析
    • 薬剤クラス別
    • 販売チャネル別
    • 国別／サブリージョン別

第11章 アジア太平洋地域の市場分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • スタチン系薬剤
    • 胆汁酸分泌抑制剤
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国・小地域別、2017-2031年
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他アジア太平洋地域
  • 市場魅力分析
    • 薬剤クラス別
    • 流通チャネル別
    • 国別／サブリージョン別

第12章 ラテンアメリカの市場分析・予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測：薬剤クラス別、2017年～2031年
    • スタチン
    • 胆汁酸セクレタント
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場価値予測：国・小地域別、2017-2031年
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 市場魅力分析
    • 薬剤クラス別
    • 流通チャネル別
    • 国別／サブリージョン別

第13章 中東・アフリカ市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：薬剤クラス別、2017-2031年
    • スタチン系薬剤
    • 胆汁酸分泌抑制剤
    • コレステロール吸収阻害剤
    • 繊維素酸誘導体
    • PCSK9阻害剤
    • その他の抗高脂血症薬
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場規模予測：国・小地域別、2017-2031年
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ
  • 市場魅力分析
    • 薬剤クラス別
    • 販売チャネル別
    • 国別／サブリージョン別

第14章 競合情勢

  • 市場プレイヤー-競争マトリックス（企業階層別、企業規模別）
  • 市場シェア分析：企業別, 2021年
  • 企業プロファイル
    • AbbVie, Inc.
    • Amgen, Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Dr. Reddy's Laboratories Ltd.
    • Merck & Co., Inc.
    • Mylan N.V
    • Pfizer, Inc.
    • Sanofi S.A.
    • Esperion Therapeutics
    • CJ Healthcare
    • Novartis
図表

List of Tables

  • Table 01: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 05: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 14: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 17: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03: Global Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 04: Global Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 06: Global Antihyperlipidemic Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Antihyperlipidemic Drugs Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 08: North America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 10: North America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 11: North America Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 13: North America Antihyperlipidemic Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 15: Europe Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 17: Europe Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 18: Europe Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 20: Europe Antihyperlipidemic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Antihyperlipidemic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 22: Asia Pacific Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 24: Asia Pacific Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 25: Asia Pacific Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Asia Pacific Antihyperlipidemic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Antihyperlipidemic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 29: Latin America Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 31: Latin America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 32: Latin America Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 34: Latin America Antihyperlipidemic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Antihyperlipidemic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Middle East & Africa Antihyperlipidemic Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Antihyperlipidemic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 38: Middle East & Africa Antihyperlipidemic Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 39: Middle East & Africa Antihyperlipidemic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Antihyperlipidemic Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 41: Middle East & Africa Antihyperlipidemic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Antihyperlipidemic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Global Antihyperlipidemic Drugs Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL34130

Antihyperlipidemic Drugs Market - Scope of Report:

TMR's report on the global antihyperlipidemic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global antihyperlipidemic drugs market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihyperlipidemic drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the antihyperlipidemic drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global antihyperlipidemic drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global antihyperlipidemic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global antihyperlipidemic drugs market.

The report delves into the competitive landscape of the global antihyperlipidemic drugs market. Key players operating in the global antihyperlipidemic drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global antihyperlipidemic drugs market profiled in this report.

Key Questions Answered in Global Antihyperlipidemic Drugs Market Report:

  • What is the sales/revenue generated by antihyperlipidemic drugs across all regions during the forecast period?
  • What are the opportunities in the global antihyperlipidemic drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Antihyperlipidemic Drugs Market - Research Objectives and Research Approach:

The comprehensive report on the global antihyperlipidemic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global antihyperlipidemic drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global antihyperlipidemic drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antihyperlipidemic Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Antihyperlipidemic Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Statins
    • 6.3.2. Bile Acid Sequestrants
    • 6.3.3. Cholesterol Absorption Inhibitors
    • 6.3.4. Fibric Acid Derivatives
    • 6.3.5. PCSK9 Inhibitors
    • 6.3.6. Miscellaneous Antihyperlipidemic Agents
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Antihyperlipidemic Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Class, 2017-2031
    • 9.2.1. Statins
    • 9.2.2. Bile Acid Sequestrants
    • 9.2.3. Cholesterol Absorption Inhibitors
    • 9.2.4. Fibric Acid Derivatives
    • 9.2.5. PCSK9 Inhibitors
    • 9.2.6. Miscellaneous Antihyperlipidemic Agents
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Antihyperlipidemic Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Statins
    • 10.2.2. Bile Acid Sequestrants
    • 10.2.3. Cholesterol Absorption Inhibitors
    • 10.2.4. Fibric Acid Derivatives
    • 10.2.5. PCSK9 Inhibitors
    • 10.2.6. Miscellaneous Antihyperlipidemic Agents
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Antihyperlipidemic Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Statins
    • 11.2.2. Bile Acid Sequestrants
    • 11.2.3. Cholesterol Absorption Inhibitors
    • 11.2.4. Fibric Acid Derivatives
    • 11.2.5. PCSK9 Inhibitors
    • 11.2.6. Miscellaneous Antihyperlipidemic Agents
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Antihyperlipidemic Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Statins
    • 12.2.2. Bile Acid Sequestrants
    • 12.2.3. Cholesterol Absorption Inhibitors
    • 12.2.4. Fibric Acid Derivatives
    • 12.2.5. PCSK9 Inhibitors
    • 12.2.6. Miscellaneous Antihyperlipidemic Agents
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Antihyperlipidemic Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Statins
    • 13.2.2. Bile Acid Sequestrants
    • 13.2.3. Cholesterol Absorption Inhibitors
    • 13.2.4. Fibric Acid Derivatives
    • 13.2.5. PCSK9 Inhibitors
    • 13.2.6. Miscellaneous Antihyperlipidemic Agents
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profiles
    • 14.3.1. AbbVie, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Amgen, Inc.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. AstraZeneca plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Bristol-Myers Squibb Company
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Daiichi Sankyo Company Limited
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Dr. Reddy's Laboratories Ltd.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Merck & Co., Inc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Mylan N.V
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Pfizer, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Sanofi S.A.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Esperion Therapeutics
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. CJ Healthcare
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. Financial Overview
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Novartis
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. Financial Overview
      • 14.3.13.4. SWOT Analysis
      • 14.3.13.5. Strategic Overview